| |
Histologic categories
|
|---|
|
All patients
|
Leiomyo-sarcomas
|
Undifferentiated pleomorphic Sarcoma
|
Liposarcomas
|
Vascular sarcomas
|
Fibroblastic/myofibroblastic sarcomas
|
Nerve sheath sarcomas
|
Rhabdomyo-sarcomas
|
Synovial sarcomas
|
Others/NOS
|
|---|
|
n (%)
|
n (%)
|
n (%)
|
n (%)
|
n (%)
|
n (%)
|
n (%)
|
n (%)
|
n (%)
|
n (%)
|
|---|
|
All patients
|
4274
|
922
|
652
|
554
|
357
|
227
|
106
|
98
|
49
|
1309
|
|
Receiving first-line systemica treatment
|
1227 (28.7)
|
341 (37.0)
|
158 (24.2)
|
140 (25.3)
|
130 (36.4)
|
58 (25.6)
|
24 (22.6)
|
28 (28.6)
|
21 (42.9)
|
327 (25.0)
|
|
Duration, mean (SD)
|
4.1 (4.1)
|
4.1 (4.2)
|
4.4 (5.7)
|
4.3 (4.7)
|
4.4 (3.4)
|
4.2 (3.8)
|
3.3 (2.5)
|
4.5 (2.9)
|
3.9 (3.3)
|
3.8 (3.2)
|
|
Median
|
3.0
|
3.1
|
2.6
|
3.0
|
3.5
|
3.6
|
3.1
|
3.7
|
3.0
|
2.8
|
|
Receiving second-line systemica treatment
|
476 (11.1)
|
148 (16.1)
|
64 (9.8)
|
45 (8.1)
|
60 (16.8)
|
19 (8.4)
|
–
|
15 (15.3)
|
–
|
109 (8.3)
|
|
Duration, mean (SD)
|
4.6 (5.3)
|
4.5 (4.0)
|
5.1 (8.6)
|
5.5 (5.4)
|
4.6 (5.2)
|
4.7 (3.6)
|
–
|
3.2 (2.2)
|
–
|
4.3 (4.7)
|
|
Median
|
3.0
|
3.3
|
2.9
|
4.0
|
3.4
|
4.8
|
–
|
2.6
|
–
|
2.9
|
|
Receiving third-line systemica treatment
|
189 (4.4)
|
66 (7.2)
|
24 (3.7)
|
15 (2.7)
|
21 (5.9)
|
–
|
–
|
–
|
–
|
46 (3.5)
|
|
Duration, mean (SD)
|
4.0 (3.4)
|
4.6 (3.6)
|
3.3 (3.8)
|
2.8 (2.2)
|
5.1 (3.6)
|
–
|
–
|
–
|
–
|
3.4 (2.8)
|
|
Median
|
3.0
|
3.7
|
2.3
|
2.1
|
5.1
|
–
|
–
|
–
|
–
|
2.6
|
- Oral chemotherapy was not covered by Medicare until 2007
- SD standard deviation
- aSystemic therapy includes chemotherapy, biologic therapy, or targeted therapy
